Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
BioSpace2d
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk launches NovoCare rivaling Eli Lilly’s LillyDirect
Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...
24/7 Wall St. on MSN12d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...